,Drug Name,RXCUI,Therapeutic Class
0,abatacept,614391,Selective immunosuppressants
1,abatacept,614391,"ANTIRHEUMATICS,OTHER"
16,abatacept,614391,Immunomodulator-containing product
17,abatacept,614391,Fusion protein-containing product
18,abatacept,614391,Abatacept
19,abatacept,614391,"Arthritis, Juvenile"
20,abatacept,614391,"Arthritis, Rheumatoid"
21,abatacept,614391,Recombinant Fusion Proteins
23,abatacept,614391,"Arthritis, Psoriatic"
25,abatacept,614391,Decreased Cytokine Activity
27,abatacept,614391,CD80-directed Antibody Interactions
28,abatacept,614391,CD86-directed Antibody Interactions
29,abatacept,614391,Selective T Cell Costimulation Modulator
31,abatacept,614391,T Lymphocyte Costimulation Activity Blockade
36,abrocitinib,2591476,Janus kinase inhibitor-containing product
37,abrocitinib,2591476,Sulfonamide-containing product
38,abrocitinib,2591476,"Dermatitis, Atopic"
39,abrocitinib,2591476,Pyrimidines
40,abrocitinib,2591476,Sulfonamides
41,abrocitinib,2591476,"Agents for dermatitis, excluding corticosteroids"
42,abrocitinib,2591476,P-Glycoprotein Inhibitors
44,abrocitinib,2591476,Janus Kinase Inhibitors
46,abrocitinib,2591476,Janus Kinase Inhibitor
49,abrocitinib,2591476,"DERMATOLOGICALS,SYSTEMIC,OTHER"
60,adalimumab,327361,Tumor necrosis factor alpha (TNF-alpha) inhibitors
62,adalimumab,327361,"ANTIRHEUMATICS,OTHER"
115,adalimumab,327361,Adalimumab
116,adalimumab,327361,"Antibodies, Monoclonal"
118,adalimumab,327361,"Arthritis, Juvenile"
119,adalimumab,327361,"Arthritis, Rheumatoid"
120,adalimumab,327361,"Colitis, Ulcerative"
121,adalimumab,327361,Crohn Disease
122,adalimumab,327361,Drug Hypersensitivity
123,adalimumab,327361,"Spondylitis, Ankylosing"
124,adalimumab,327361,Uveitis
125,adalimumab,327361,"Arthritis, Psoriatic"
126,adalimumab,327361,Hidradenitis Suppurativa
127,adalimumab,327361,Biological Response Modifiers
128,adalimumab,327361,Immunologic Activity Alteration
129,adalimumab,327361,Tumor Necrosis Factor alpha Receptor Blocking Activity
130,adalimumab,327361,Tumor Necrosis Factor Receptor Blocking Activity
132,adalimumab,327361,Tumor Necrosis Factor Blocker
488,adalimumab,327361,Monoclonal antibody-containing product
489,adalimumab,327361,Tumor necrosis factor alpha inhibitor-containing product
516,alemtuzumab,117055,Immunomodulator-containing product
517,alemtuzumab,117055,Monoclonal antibody antineoplastic agent
519,alemtuzumab,117055,Alemtuzumab
520,alemtuzumab,117055,Drug Hypersensitivity
521,alemtuzumab,117055,Immunologic Deficiency Syndromes
522,alemtuzumab,117055,Infections
523,alemtuzumab,117055,"Leukemia, Lymphocytic, Chronic, B-Cell"
524,alemtuzumab,117055,Monoclonal antibodies
525,alemtuzumab,117055,Increased Lymphocyte Cell Destruction
526,alemtuzumab,117055,Antibody-Receptor Interactions
527,alemtuzumab,117055,CD52-directed Antibody Interactions
530,alemtuzumab,117055,CD52-directed Cytolytic Antibody
532,alemtuzumab,117055,"ANTINEOPLASTIC,OTHER"
540,anakinra,72435,Recombinant interleukin 1 receptor antagonist-containing product
542,anakinra,72435,"Arthritis, Rheumatoid"
543,anakinra,72435,Drug Hypersensitivity
544,anakinra,72435,Infections
545,anakinra,72435,Escherichia coli Proteins
546,anakinra,72435,Interleukin 1 Receptor Antagonist Protein
547,anakinra,72435,Cryopyrin-Associated Periodic Syndromes
548,anakinra,72435,Interleukin inhibitors
549,anakinra,72435,Enzyme Inhibitors
550,anakinra,72435,Bone Resorption Inhibition
551,anakinra,72435,Decreased Immunologically Active Molecule Activity
552,anakinra,72435,Interleukin 1 Receptor Antagonists
555,anakinra,72435,Interleukin-1 Receptor Antagonist
558,anakinra,72435,"ANTIRHEUMATICS,OTHER"
561,apremilast,1492727,Immunomodulator-containing product
562,apremilast,1492727,Ether structure-containing product
563,apremilast,1492727,Phosphodiesterase 4 inhibitor-containing product
564,apremilast,1492727,Sulfur and/or sulfur compound-containing product
565,apremilast,1492727,Drug Hypersensitivity
566,apremilast,1492727,Thalidomide
567,apremilast,1492727,"Arthritis, Psoriatic"
568,apremilast,1492727,Selective immunosuppressants
569,apremilast,1492727,Decreased Leukotriene Production
570,apremilast,1492727,Phosphodiesterase 4 Inhibitors
573,apremilast,1492727,Phosphodiesterase 4 Inhibitor
576,apremilast,1492727,"ANTIRHEUMATICS,OTHER"
599,baricitinib,2047232,Immunomodulator-containing product
600,baricitinib,2047232,Janus kinase inhibitor-containing product
601,baricitinib,2047232,"Arthritis, Rheumatoid"
602,baricitinib,2047232,Azetidines
603,baricitinib,2047232,Purines
604,baricitinib,2047232,Pyrazoles
605,baricitinib,2047232,Sulfonamides
606,baricitinib,2047232,Janus-associated kinase (JAK) inhibitors
607,baricitinib,2047232,Increased Extracellular Communication
608,baricitinib,2047232,Janus Kinase Inhibitors
611,baricitinib,2047232,Janus Kinase Inhibitor
614,baricitinib,2047232,"ANTIRHEUMATICS,OTHER"
625,benralizumab,1989100,Monoclonal antibody-containing product
626,benralizumab,1989100,Interleukin receptor antagonist-containing product
627,benralizumab,1989100,Asthma
628,benralizumab,1989100,Drug Hypersensitivity
629,benralizumab,1989100,"Antibodies, Monoclonal, Humanized"
630,benralizumab,1989100,Interleukin 5 Receptor alpha-directed Antibody Interactions
632,benralizumab,1989100,Interleukin-5 Receptor alpha-directed Cytolytic Antibody
634,benralizumab,1989100,Other systemic drugs for obstructive airway diseases
636,benralizumab,1989100,"ANTIASTHMA,OTHER"
647,brodalumab,1872251,Monoclonal antibody-containing product
648,brodalumab,1872251,Interleukin receptor antagonist-containing product
649,brodalumab,1872251,"Antibodies, Monoclonal"
651,brodalumab,1872251,Crohn Disease
652,brodalumab,1872251,Psoriasis
653,brodalumab,1872251,"Antibodies, Monoclonal, Humanized"
654,brodalumab,1872251,Interleukin inhibitors
655,brodalumab,1872251,Interleukin-17 Receptor A Antagonist
657,brodalumab,1872251,Interleukin 17 Receptor A Interactions
658,brodalumab,1872251,Interleukin 17 Receptor A Antagonists
660,brodalumab,1872251,"ANTIPSORIATICS,SYSTEMIC"
664,canakinumab,853491,IMMUNE SUPPRESSANTS
665,canakinumab,853491,Interleukin inhibitors
668,canakinumab,853491,Monoclonal antibody-containing product
669,canakinumab,853491,Interleukin 1 receptor antagonist-containing product
670,canakinumab,853491,"Arthritis, Juvenile"
671,canakinumab,853491,Drug Hypersensitivity
672,canakinumab,853491,Familial Mediterranean Fever
673,canakinumab,853491,Mevalonate Kinase Deficiency
674,canakinumab,853491,Cryopyrin-Associated Periodic Syndromes
675,canakinumab,853491,"Antibodies, Monoclonal, Humanized"
677,canakinumab,853491,Decreased Immunologic Activity
678,canakinumab,853491,Interleukin 1 Receptor Antagonists
679,certolizumab pegol,709271,Monoclonal antibody-containing product
680,certolizumab pegol,709271,Tumor necrosis factor alpha inhibitor-containing product
681,certolizumab pegol,709271,Certolizumab Pegol
682,certolizumab pegol,709271,"Arthritis, Rheumatoid"
683,certolizumab pegol,709271,Crohn Disease
684,certolizumab pegol,709271,Drug Hypersensitivity
685,certolizumab pegol,709271,"Spondylitis, Ankylosing"
686,certolizumab pegol,709271,"Arthritis, Psoriatic"
687,certolizumab pegol,709271,Tumor necrosis factor alpha (TNF-alpha) inhibitors
688,certolizumab pegol,709271,Biological Response Modifiers
689,certolizumab pegol,709271,Immunologic Activity Alteration
690,certolizumab pegol,709271,Tumor Necrosis Factor alpha Receptor Blocking Activity
691,certolizumab pegol,709271,Tumor Necrosis Factor Receptor Blocking Activity
693,certolizumab pegol,709271,Tumor Necrosis Factor Blocker
695,certolizumab pegol,709271,TUMOR NECROSIS FACTOR BLOCKER
703,deucravacitinib,2612087,Heterocyclic Compounds
704,deucravacitinib,2612087,Parapsoriasis
705,deucravacitinib,2612087,Janus-associated kinase (JAK) inhibitors
706,deucravacitinib,2612087,Tyrosine Kinase Inhibitors
707,deucravacitinib,2612087,Increased Immunologic Activity
708,deucravacitinib,2612087,Janus Kinase Inhibitors
709,deucravacitinib,2612087,Tyrosine Kinase 2 Inhibitor
711,deucravacitinib,2612087,Tyrosine Kinase 2 Inhibitors
713,deucravacitinib,2612087,"ANTIPSORIATICS,SYSTEMIC"
717,deuruxolitinib,N/A,N/A
718,dupilumab,1876376,Monoclonal antibody-containing product
719,dupilumab,1876376,Interleukin-4 receptor alpha antagonist-containing product
720,dupilumab,1876376,"Antibodies, Monoclonal"
722,dupilumab,1876376,"Dermatitis, Atopic"
723,dupilumab,1876376,Drug Hypersensitivity
724,dupilumab,1876376,"Antibodies, Monoclonal, Humanized"
725,dupilumab,1876376,"Agents for dermatitis, excluding corticosteroids"
726,dupilumab,1876376,Decreased Immunologic Activity
727,dupilumab,1876376,Interleukin 4 Receptor alpha Antagonists
730,dupilumab,1876376,Interleukin-4 Receptor alpha Antagonist
733,dupilumab,1876376,"DERMATOLOGICALS,SYSTEMIC,OTHER"
752,etanercept,214555,Tumor necrosis factor alpha (TNF-alpha) inhibitors
753,etanercept,214555,"ANTIRHEUMATICS,OTHER"
756,etanercept,214555,Etanercept
757,etanercept,214555,"Arthritis, Juvenile"
758,etanercept,214555,"Arthritis, Rheumatoid"
759,etanercept,214555,Drug Hypersensitivity
760,etanercept,214555,"Spondylitis, Ankylosing"
761,etanercept,214555,"Arthritis, Psoriatic"
762,etanercept,214555,Sepsis
763,etanercept,214555,Biological Response Modifiers
764,etanercept,214555,Immunologic Activity Alteration
765,etanercept,214555,Tumor Necrosis Factor alpha Receptor Blocking Activity
766,etanercept,214555,Tumor Necrosis Factor beta Receptor Blocking Activity
767,etanercept,214555,Tumor necrosis factor alpha inhibitor-containing product
768,etanercept,214555,Fusion protein-containing product
781,etanercept,214555,Tumor Necrosis Factor Receptor Blocking Activity
783,etanercept,214555,Tumor Necrosis Factor Blocker
808,etrasimod,2668045,Acetates
809,etrasimod,2668045,"Colitis, Ulcerative"
810,etrasimod,2668045,Indoles
811,etrasimod,2668045,Sphingosine-1-phosphate (S1P) receptor modulators
812,etrasimod,2668045,Hormone Receptor Modulators
813,etrasimod,2668045,Decreased Cellular Migration
817,etrasimod,2668045,"IMMUNOLOGICAL AGENTS,OTHER"
821,golimumab,819300,Tumor necrosis factor alpha (TNF-alpha) inhibitors
822,golimumab,819300,"ANTIRHEUMATICS,OTHER"
837,golimumab,819300,Monoclonal antibody-containing product
838,golimumab,819300,Tumor necrosis factor alpha inhibitor-containing product
839,golimumab,819300,"Antibodies, Monoclonal"
840,golimumab,819300,"Arthritis, Rheumatoid"
842,golimumab,819300,Biological Response Modifiers
843,golimumab,819300,Immunologic Activity Alteration
844,golimumab,819300,Tumor Necrosis Factor alpha Receptor Blocking Activity
845,golimumab,819300,Tumor Necrosis Factor Receptor Blocking Activity
847,golimumab,819300,Tumor Necrosis Factor Blocker
853,guselkumab,1928588,Monoclonal antibody-containing product
854,guselkumab,1928588,Interleukin receptor antagonist-containing product
855,guselkumab,1928588,Psoriasis
856,guselkumab,1928588,"Antibodies, Monoclonal, Humanized"
857,guselkumab,1928588,Interleukin inhibitors
858,guselkumab,1928588,Antibody-Receptor Interactions
859,guselkumab,1928588,Interleukin-23 Antagonists
862,guselkumab,1928588,Interleukin-23 Antagonist
864,guselkumab,1928588,IMMUNE SUPPRESSANTS
884,infliximab,191831,Infliximab
885,infliximab,191831,"Arthritis, Rheumatoid"
886,infliximab,191831,"Colitis, Ulcerative"
887,infliximab,191831,Crohn Disease
888,infliximab,191831,Drug Hypersensitivity
889,infliximab,191831,Heart Failure
890,infliximab,191831,"Spondylitis, Ankylosing"
891,infliximab,191831,"Arthritis, Psoriatic"
892,infliximab,191831,Biological Response Modifiers
893,infliximab,191831,Decreased Cytokine Activity
894,infliximab,191831,Increased Adhesion Factor Production
895,infliximab,191831,Decreased Vascular Permeability
896,infliximab,191831,Tumor Necrosis Factor alpha Receptor Blocking Activity
897,infliximab,191831,IMMUNE SUPPRESSANTS
898,infliximab,191831,Tumor necrosis factor alpha (TNF-alpha) inhibitors
901,infliximab,191831,Monoclonal antibody-containing product
902,infliximab,191831,Tumor necrosis factor alpha inhibitor-containing product
916,infliximab,191831,Tumor Necrosis Factor Receptor Blocking Activity
918,infliximab,191831,Tumor Necrosis Factor Blocker
974,ixekizumab,1745099,Monoclonal antibody-containing product
975,ixekizumab,1745099,Interleukin receptor antagonist-containing product
976,ixekizumab,1745099,Drug Hypersensitivity
977,ixekizumab,1745099,Psoriasis
978,ixekizumab,1745099,"Antibodies, Monoclonal, Humanized"
979,ixekizumab,1745099,Interleukin inhibitors
980,ixekizumab,1745099,Interleukin-17A Antagonists
983,ixekizumab,1745099,Interleukin-17A Antagonist
985,ixekizumab,1745099,IMMUNE SUPPRESSANTS
1001,mepolizumab,1720597,Monoclonal antibody-containing product
1002,mepolizumab,1720597,Interleukin 5 receptor antagonist-containing product
1003,mepolizumab,1720597,Asthma
1004,mepolizumab,1720597,Drug Hypersensitivity
1005,mepolizumab,1720597,"Antibodies, Monoclonal, Humanized"
1006,mepolizumab,1720597,Interleukin-5 Antagonists
1009,mepolizumab,1720597,Interleukin-5 Antagonist
1011,mepolizumab,1720597,Other systemic drugs for obstructive airway diseases
1013,mepolizumab,1720597,"ANTIASTHMA,OTHER"
1028,mirikizumab-mrkz,2668385,"Colitis, Ulcerative"
1029,mirikizumab-mrkz,2668385,"Antibodies, Monoclonal, Humanized"
1030,mirikizumab-mrkz,2668385,Interleukin inhibitors
1031,mirikizumab-mrkz,2668385,Decreased Cytokine Activity
1032,mirikizumab-mrkz,2668385,Antibody-Receptor Interactions
1033,mirikizumab-mrkz,2668385,Interleukin-23 Antagonists
1036,mirikizumab-mrkz,2668385,Interleukin-23 Antagonist
1042,mirikizumab-mrkz,2668385,IMMUNE SUPPRESSANTS
1054,natalizumab,354770,Monoclonal antibody-containing product
1055,natalizumab,354770,Immunomodulator-containing product
1056,natalizumab,354770,Alpha-4 integrin receptor antagonist-containing product
1057,natalizumab,354770,Natalizumab
1058,natalizumab,354770,Crohn Disease
1059,natalizumab,354770,Drug Hypersensitivity
1060,natalizumab,354770,"Leukoencephalopathy, Progressive Multifocal"
1061,natalizumab,354770,Multiple Sclerosis
1062,natalizumab,354770,Monoclonal antibodies
1063,natalizumab,354770,Decreased Adhesion Factor Activity
1064,natalizumab,354770,Integrin Receptor Antagonists
1067,natalizumab,354770,Integrin Receptor Antagonist
1069,natalizumab,354770,IMMUNE STIMULANTS
1073,ocrelizumab,1876366,Monoclonal antibody-containing product
1074,ocrelizumab,1876366,Immunomodulator-containing product
1075,ocrelizumab,1876366,"Antibodies, Monoclonal"
1077,ocrelizumab,1876366,Drug Hypersensitivity
1078,ocrelizumab,1876366,Hepatitis B
1079,ocrelizumab,1876366,Multiple Sclerosis
1080,ocrelizumab,1876366,"Antibodies, Monoclonal, Humanized"
1083,ocrelizumab,1876366,Monoclonal antibodies
1084,ocrelizumab,1876366,CD20-directed Antibody Interactions
1087,ocrelizumab,1876366,CD20-directed Cytolytic Antibody
1090,ocrelizumab,1876366,"MUSCULOSKELETAL AGENTS,OTHER"
1096,ocrelizumab,1876366,Decreased Immunologic Activity
1101,ofatumumab,712566,"ANTINEOPLASTIC,OTHER"
1102,ofatumumab,712566,CD20 (Clusters of Differentiation 20) inhibitors
1113,ofatumumab,712566,Immunomodulator-containing product
1114,ofatumumab,712566,Monoclonal antibody antineoplastic agent
1116,ofatumumab,712566,"Leukemia, Lymphoid"
1117,ofatumumab,712566,"Antibodies, Monoclonal, Humanized"
1119,ofatumumab,712566,Monoclonal antibodies
1120,ofatumumab,712566,CD20-directed Antibody Interactions
1123,ofatumumab,712566,CD20-directed Cytolytic Antibody
1125,omalizumab,302379,IMMUNE SUPPRESSANTS
1126,omalizumab,302379,Other systemic drugs for obstructive airway diseases
1138,omalizumab,302379,Monoclonal antibodies
1153,omalizumab,302379,Monoclonal antibody-containing product
1154,omalizumab,302379,Immunomodulator-containing product
1155,omalizumab,302379,Omalizumab
1156,omalizumab,302379,Asthma
1157,omalizumab,302379,Drug Hypersensitivity
1158,omalizumab,302379,IgE-directed Antibody Interactions
1161,omalizumab,302379,Decreased IgE Activity
1164,omalizumab,302379,Anti-IgE
1167,ozanimod,2288235,"Angina, Unstable"
1168,ozanimod,2288235,"Ischemic Attack, Transient"
1169,ozanimod,2288235,Heart Failure
1170,ozanimod,2288235,Myocardial Infarction
1171,ozanimod,2288235,Sick Sinus Syndrome
1172,ozanimod,2288235,Sinoatrial Block
1173,ozanimod,2288235,Sleep Apnea Syndromes
1174,ozanimod,2288235,Stroke
1175,ozanimod,2288235,"Multiple Sclerosis, Relapsing-Remitting"
1176,ozanimod,2288235,Atrioventricular Block
1177,ozanimod,2288235,Monoamine Oxidase Inhibitors
1178,ozanimod,2288235,Decreased Lymphocyte Activation
1179,ozanimod,2288235,Sphingosine 1-Phosphate Receptor Modulators
1180,ozanimod,2288235,Immunomodulator-containing product
1184,ozanimod,2288235,Indans
1186,ozanimod,2288235,Oxadiazoles
1193,ozanimod,2288235,Sphingosine-1-phosphate (S1P) receptor modulators
1199,ozanimod,2288235,Sphingosine 1-phosphate Receptor Modulator
1201,reslizumab,1746889,Monoclonal antibody-containing product
1202,reslizumab,1746889,Interleukin 5 receptor antagonist-containing product
1203,reslizumab,1746889,Asthma
1204,reslizumab,1746889,Drug Hypersensitivity
1205,reslizumab,1746889,"Antibodies, Monoclonal, Humanized"
1206,reslizumab,1746889,Interleukin-5 Antagonists
1209,reslizumab,1746889,Interleukin-5 Antagonist
1211,reslizumab,1746889,Other systemic drugs for obstructive airway diseases
1213,reslizumab,1746889,"RESPIRATORY AGENTS,OTHER"
1216,risankizumab,2166040,Monoclonal antibody-containing product
1217,risankizumab,2166040,Interleukin 23 receptor antagonist-containing product
1218,risankizumab,2166040,"Antibodies, Monoclonal"
1219,risankizumab,2166040,Psoriasis
1220,risankizumab,2166040,Interleukin inhibitors
1221,risankizumab,2166040,Decreased Cytokine Activity
1222,risankizumab,2166040,Interleukin-23 Antagonists
1225,risankizumab,2166040,Interleukin-23 Antagonist
1232,risankizumab,2166040,"ANTIRHEUMATICS,OTHER"
1262,rituximab,121191,Immunomodulator-containing product
1263,rituximab,121191,Monoclonal antibody antineoplastic agent
1265,rituximab,121191,Rituximab
1266,rituximab,121191,"Arthritis, Rheumatoid"
1267,rituximab,121191,Drug Hypersensitivity
1268,rituximab,121191,"Leukemia, Lymphoid"
1269,rituximab,121191,Granulomatosis with Polyangiitis
1270,rituximab,121191,"Lymphoma, B-Cell"
1271,rituximab,121191,"Lymphoma, Mantle-Cell"
1272,rituximab,121191,Microscopic Polyangiitis
1273,rituximab,121191,CD20 (Clusters of Differentiation 20) inhibitors
1274,rituximab,121191,Increased Cellular Death
1275,rituximab,121191,Antibody-Receptor Interactions
1276,rituximab,121191,CD20-directed Antibody Interactions
1278,rituximab,121191,CD20-directed Cytolytic Antibody
1280,rituximab,121191,"ANTINEOPLASTIC,OTHER"
1348,roflumilast,1091836,Phosphodiesterase 4 inhibitor-containing product
1349,roflumilast,1091836,Benzamide structure-containing product
1350,roflumilast,1091836,Aminopyridines
1351,roflumilast,1091836,Benzamides
1352,roflumilast,1091836,Cyclopropanes
1353,roflumilast,1091836,Liver Diseases
1354,roflumilast,1091836,"Pulmonary Disease, Chronic Obstructive"
1355,roflumilast,1091836,Other antipsoriatics for topical use
1356,roflumilast,1091836,Decreased Tracheo-Bronchial Secretions
1357,roflumilast,1091836,Phosphodiesterase 4 Inhibitors
1360,roflumilast,1091836,Phosphodiesterase 4 Inhibitor
1362,roflumilast,1091836,Other systemic drugs for obstructive airway diseases
1364,roflumilast,1091836,"RESPIRATORY AGENTS,OTHER"
1372,roflumilast,1091836,"ANTIPSORIATICS,TOPICAL"
1383,ruxolitinib,1193325,Nitriles
1384,ruxolitinib,1193325,Polycythemia Vera
1385,ruxolitinib,1193325,Primary Myelofibrosis
1386,ruxolitinib,1193325,Decreased Hematopoiesis
1387,ruxolitinib,1193325,Cellular Proliferation Alteration
1388,ruxolitinib,1193325,Janus Kinase Inhibitors
1389,ruxolitinib,1193325,Antineoplastic agent
1390,ruxolitinib,1193325,Janus kinase inhibitor-containing product
1391,ruxolitinib,1193325,Azole-containing product
1394,ruxolitinib,1193325,Pyrazoles
1395,ruxolitinib,1193325,Pyrimidines
1397,ruxolitinib,1193325,"Agents for dermatitis, excluding corticosteroids"
1398,ruxolitinib,1193325,Janus-associated kinase (JAK) inhibitors
1400,ruxolitinib,1193325,Kinase Inhibitor
1406,ruxolitinib,1193325,Janus Kinase Inhibitor
1408,sarilumab,1923319,Monoclonal antibody-containing product
1409,sarilumab,1923319,Interleukin receptor antagonist-containing product
1410,sarilumab,1923319,"Arthritis, Rheumatoid"
1411,sarilumab,1923319,Drug Hypersensitivity
1412,sarilumab,1923319,"Antibodies, Monoclonal, Humanized"
1413,sarilumab,1923319,Interleukin inhibitors
1414,sarilumab,1923319,Decreased Cytokine Activity
1415,sarilumab,1923319,Interleukin 6 Receptor Antagonists
1418,sarilumab,1923319,Interleukin-6 Receptor Antagonist
1421,sarilumab,1923319,"ANTIRHEUMATICS,OTHER"
1436,secukinumab,1599788,Monoclonal antibody-containing product
1437,secukinumab,1599788,Immunomodulator-containing product
1438,secukinumab,1599788,Drug Hypersensitivity
1439,secukinumab,1599788,"Spondylitis, Ankylosing"
1440,secukinumab,1599788,"Arthritis, Psoriatic"
1441,secukinumab,1599788,"Antibodies, Monoclonal, Humanized"
1442,secukinumab,1599788,Interleukin inhibitors
1443,secukinumab,1599788,Interleukin-17A Antagonists
1446,secukinumab,1599788,Interleukin-17A Antagonist
1448,secukinumab,1599788,IMMUNE SUPPRESSANTS
1468,spesolimab-sbzo,2610418,Psoriasis
1469,spesolimab-sbzo,2610418,"Antibodies, Monoclonal, Humanized"
1470,spesolimab-sbzo,2610418,Interleukin inhibitors
1471,spesolimab-sbzo,2610418,Antibody Interactions
1472,spesolimab-sbzo,2610418,Interleukin-36 Receptor Antagonist
1474,spesolimab-sbzo,2610418,Interleukin-36 Receptor Antagonists
1478,spesolimab-sbzo,2610418,"ANTIPSORIATICS,SYSTEMIC"
1486,tezepelumab ekko,2587790,Monoclonal antibody-containing product
1487,tezepelumab ekko,2587790,Immunoglobulin-containing product
1488,tezepelumab ekko,2587790,Asthma
1489,tezepelumab ekko,2587790,"Antibodies, Monoclonal, Humanized"
1490,tezepelumab ekko,2587790,Respiratory/Pulmonary Activity Alteration
1491,tezepelumab ekko,2587790,Antibody-Receptor Interactions
1492,tezepelumab ekko,2587790,Thymic Stromal Lymphopoietin Blocker
1494,tezepelumab ekko,2587790,Thymic Stromal Lymphopoietin Blockers
1496,tezepelumab ekko,2587790,Other systemic drugs for obstructive airway diseases
1504,tezepelumab ekko,2587790,"ANTIASTHMA,OTHER"
1511,tildrakizumab-asmn,2053449,Monoclonal antibody-containing product
1512,tildrakizumab-asmn,2053449,Interleukin 23 receptor antagonist-containing product
1513,tildrakizumab-asmn,2053449,Drug Hypersensitivity
1514,tildrakizumab-asmn,2053449,Psoriasis
1515,tildrakizumab-asmn,2053449,"Antibodies, Monoclonal, Humanized"
1516,tildrakizumab-asmn,2053449,Interleukin inhibitors
1517,tildrakizumab-asmn,2053449,Decreased Cytokine Activity
1518,tildrakizumab-asmn,2053449,Interleukin-23 Antagonists
1521,tildrakizumab-asmn,2053449,Interleukin-23 Antagonist
1527,tildrakizumab-asmn,2053449,"IMMUNOLOGICAL AGENTS,OTHER"
1531,tocilizumab,612865,Interleukin inhibitors
1532,tocilizumab,612865,"ANTIRHEUMATICS,OTHER"
1551,tocilizumab,612865,Cytokine Release Syndrome
1552,tocilizumab,612865,"Arthritis, Juvenile"
1553,tocilizumab,612865,"Arthritis, Rheumatoid"
1554,tocilizumab,612865,Giant Cell Arteritis
1555,tocilizumab,612865,Decreased Cytokine Production
1556,tocilizumab,612865,Decreased Immunologic Activity
1557,tocilizumab,612865,Interleukin 6 Receptor Antagonists
1597,tocilizumab,612865,Monoclonal antibody-containing product
1602,tocilizumab,612865,"Antibodies, Monoclonal, Humanized"
1609,tocilizumab,612865,Interleukin-6 Receptor Antagonist
1611,tocilizumab bavi,2680283,Cytokine Release Syndrome
1612,tocilizumab bavi,2680283,"Arthritis, Juvenile"
1613,tocilizumab bavi,2680283,"Arthritis, Rheumatoid"
1614,tocilizumab bavi,2680283,Giant Cell Arteritis
1615,tocilizumab bavi,2680283,Decreased Cytokine Production
1616,tocilizumab bavi,2680283,Decreased Immunologic Activity
1617,tocilizumab bavi,2680283,Interleukin 6 Receptor Antagonists
1618,tocilizumab bavi,2680283,Interleukin inhibitors
1619,tocilizumab bavi,2680283,"ANTIRHEUMATICS,OTHER"
1630,tocilizumab bavi,2680283,Monoclonal antibody-containing product
1635,tocilizumab bavi,2680283,"Antibodies, Monoclonal, Humanized"
1642,tocilizumab bavi,2680283,Interleukin-6 Receptor Antagonist
1644,tocilizumab aazg,2679427,Cytokine Release Syndrome
1645,tocilizumab aazg,2679427,"Arthritis, Juvenile"
1646,tocilizumab aazg,2679427,"Arthritis, Rheumatoid"
1647,tocilizumab aazg,2679427,Giant Cell Arteritis
1648,tocilizumab aazg,2679427,Decreased Cytokine Production
1649,tocilizumab aazg,2679427,Decreased Immunologic Activity
1650,tocilizumab aazg,2679427,Interleukin 6 Receptor Antagonists
1651,tocilizumab aazg,2679427,Interleukin inhibitors
1652,tocilizumab aazg,2679427,"ANTIRHEUMATICS,OTHER"
1671,tocilizumab aazg,2679427,Monoclonal antibody-containing product
1676,tocilizumab aazg,2679427,"Antibodies, Monoclonal, Humanized"
1683,tocilizumab aazg,2679427,Interleukin-6 Receptor Antagonist
1685,tofacitinib,1357536,Immunomodulator-containing product
1686,tofacitinib,1357536,Janus kinase inhibitor-containing product
1687,tofacitinib,1357536,Nitrogen and/or nitrogen compound-containing product
1688,tofacitinib,1357536,"Arthritis, Rheumatoid"
1689,tofacitinib,1357536,Piperidines
1690,tofacitinib,1357536,Pyrimidines
1691,tofacitinib,1357536,Janus-associated kinase (JAK) inhibitors
1692,tofacitinib,1357536,Decreased Hematopoiesis
1693,tofacitinib,1357536,Decreased Immunologic Activity
1694,tofacitinib,1357536,Janus Kinase Inhibitors
1697,tofacitinib,1357536,Janus Kinase Inhibitor
1699,tofacitinib,1357536,"IMMUNOLOGICAL AGENTS,OTHER"
1724,tralokinumab,2589225,Monoclonal antibody-containing product
1725,tralokinumab,2589225,Interleukin receptor antagonist-containing product
1726,tralokinumab,2589225,"Antibodies, Monoclonal"
1727,tralokinumab,2589225,"Dermatitis, Atopic"
1728,tralokinumab,2589225,"Agents for dermatitis, excluding corticosteroids"
1729,tralokinumab,2589225,Interleukin-13 Antagonist
1731,tralokinumab,2589225,Interleukin-13 Antagonists
1737,tralokinumab,2589225,"DERMATOLOGICALS,SYSTEMIC,OTHER"
1744,upadacitinib,2196092,Immunomodulator-containing product
1745,upadacitinib,2196092,Janus kinase inhibitor-containing product
1746,upadacitinib,2196092,Antirheumatic agent
1747,upadacitinib,2196092,"Arthritis, Rheumatoid"
1748,upadacitinib,2196092,"Heterocyclic Compounds, 3-Ring"
1749,upadacitinib,2196092,Janus-associated kinase (JAK) inhibitors
1750,upadacitinib,2196092,Increased Extracellular Communication
1751,upadacitinib,2196092,Janus Kinase Inhibitors
1754,upadacitinib,2196092,Janus Kinase Inhibitor
1757,upadacitinib,2196092,"ANTIRHEUMATICS,OTHER"
1772,ustekinumab,847083,IMMUNE SUPPRESSANTS
1773,ustekinumab,847083,Interleukin inhibitors
1820,ustekinumab,847083,Monoclonal antibody-containing product
1821,ustekinumab,847083,Ustekinumab
1822,ustekinumab,847083,Crohn Disease
1823,ustekinumab,847083,Drug Hypersensitivity
1824,ustekinumab,847083,"Arthritis, Psoriatic"
1826,ustekinumab,847083,Interleukin-12 Antagonists
1829,ustekinumab,847083,Interleukin-12 Antagonist
1831,ustekinumab,847083,Interleukin-23 Antagonists
1834,ustekinumab,847083,Interleukin-23 Antagonist
1844,vedolizumab,1538097,Monoclonal antibody-containing product
1845,vedolizumab,1538097,Immunomodulator-containing product
1846,vedolizumab,1538097,Alpha-4 integrin receptor antagonist-containing product
1847,vedolizumab,1538097,"Colitis, Ulcerative"
1848,vedolizumab,1538097,Crohn Disease
1849,vedolizumab,1538097,Drug Hypersensitivity
1850,vedolizumab,1538097,Enteritis
1851,vedolizumab,1538097,"Antibodies, Monoclonal, Humanized"
1852,vedolizumab,1538097,Monoclonal antibodies
1853,vedolizumab,1538097,Decreased Adhesion Factor Activity
1854,vedolizumab,1538097,Integrin Receptor Antagonists
1857,vedolizumab,1538097,Integrin Receptor Antagonist
1859,vedolizumab,1538097,"GASTRIC MEDICATIONS,OTHER"
